Introduction {#Sec1}
============

Respiratory virus infections (RVIs) are common after allogeneic hematopoietic SCT (allo-HSCT),^[@CR1],\ [@CR2],\ [@CR3]^ and influenza may account for up to 30% of all RVIs.^[@CR4],\ [@CR5]^ Influenza pneumonia-related mortality can reach 25%, particularly in those patients with chronic GvHD.^[@CR1],\ [@CR2]^ Recently, a new type of influenza A (H1N1) virus, characterized by antigenically distant surface Ags compared with human viruses,^[@CR6]^ has been involved in a worldwide pandemic outbreak that began in Mexico in March 2009.^[@CR7]^ On 11 June 2009, WHO (World Health Organization) declared it as the first pandemic of the twenty-first century and \>17 700 deaths were reported as of March 2010.^[@CR8]^

Although several large studies have characterized 2009-H1N1 as a novel infection in the general population,^[@CR9],\ [@CR10],\ [@CR11]^ the true extent of 2009-H1N1 infection is not yet well defined in allo-HSCT recipients. To better define H1N1 infection in this highly immunocompromised patient population, we reviewed our recent experience at the Geneva University Hospital. This observational study describes the incidence, clinical features and outcome of H1N1 infection among allo-HSCT recipients seen in our department during the pandemic.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

The Hematology Division at the Geneva University Hospital (Geneva, Switzerland) is a referral center for adults receiving allo-HSCT (population 1.8 million) and patients are closely followed up for many years post transplant. Between May 2009 and May 2010, 248 adult allo-HSCT recipients were followed up. Overall, 19 (8%) patients were within 6 months post transplant and 33 (13%) within 1 year. A total of 46 had an active GvHD (acute grade ⩾2 or chronic extensive). According to pre-defined institutional guidelines, all allo-HSCT recipients who presented with respiratory symptoms (such as sore throat, cough, rhinorrhea, nasal congestion or dyspnea) with or without fever were investigated for the presence of H1N1 and other community-acquired respiratory viruses (such as adenovirus, metapneumovirus, seasonal influenza A and B, parainfluenza, picornavirus, respiratory syncytial virus). All specimens for microbiological confirmation were taken from combined nasopharyngeal and throat swabs at the time of initial screening. In addition, bronchoalveolar lavages were performed in patients requiring mechanical ventilation. Serial specimens were collected at the discretion of the treating physician. All patients gave their informed consent and the study was approved by the Institutional Review Board.

Virological methods {#Sec4}
-------------------

All analyses were performed according to standardized protocols^[@CR12]^ running in our virology laboratory, which is a WHO referral center for influenza. In brief, H1N1 virus was detected in samples using a real-time reverse transcription-PCR assay in accordance with the protocol from the US Centres for Disease Control and Prevention.^[@CR13]^ Whenever possible, H1N1 virus isolates were analyzed to determine the presence of the H275Y NA (neuraminidase) mutation using a nucleic acid sequencing assay.

Data collection and analysis {#Sec5}
----------------------------

Chart review was performed for all patients who received a PCR-documented diagnosis of H1N1 infection during the study period. Transplant-related characteristics, immunosuppressive medication regimen, H1N1 infection-related features, copathogens and outcomes were assessed. Death due to H1N1 infection was defined as patients dying of respiratory failure after H1N1 infection or its complications. Respiratory tract infections were classified according to Ljungman *et al.*^[@CR2]^: upper respiratory tract infection (URTI) was defined as detection of H1N1 from upper respiratory secretions together with symptoms from the upper respiratory tract. Lower respiratory tract infection (LRTI) was defined as hypoxia, pulmonary infiltrates or new abnormal chest auscultation findings, together with identification of the H1N1 virus in bronchoalveolar lavage or upper respiratory secretions. Hospital-acquired infection was defined as symptom onset \>7 days after admission. The immunodeficiency status was graded as published elsewhere,^[@CR4]^ either as severe (SID) or MID (moderate). Lymphopenia was defined by lymphocyte counts \<1 G/L. Data were analyzed with descriptive statistics and proportions were compared with a Fisher\'s exact two-tailed test using SPSS Statistics 13.0 software (SPSS, Chicago, IL, USA).

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

During the study period, 51 (20%) of 248 allo-HSCT recipients followed up at our outpatient clinic were screened. We identified 10 patients with H1N1 infection between 18 August 2009 and 29 December 2009, giving a frequency of 20% (10/51) (95% confidence interval, 9--30%) based on the number of patients screened or 4% (10/248) (95% confidence interval, 2--7%) based on the total number of patients followed up. Close contact with children ⩽12 years or adolescents in the previous 7 days was the most frequently suspected mode of transmission (50% of cases), whereas one case was considered nosocomial (UPN 10).

The median age of H1N1-infected patients was 50.5 (range, 23--62) years, and the median time since transplant was 15 (range, 6--109) months. Eight donors were HLA-identical siblings and all patients, but one (UPN 9), received PBSCs. Half of the patients received a so-called reduced-intensity conditioning regimen. At the time of infection, all patients were in CR for their underlying disease. Six patients had received a partial T cell-depleted transplant and four an unmanipulated graft. Most of the patients were heavily pre-treated before allo-HSCT, and one patient (UPN 4) was on lenalidomide as post-transplant maintenance therapy for multiple myeloma. Four patients had a Karnofsky score ⩽80% and presented various comorbid conditions. With respect to their immunodeficiency status, five patients were classified as having SID and five as MID. Five patients had GvHD (one acute grade 4 and four chronic extensive) and were receiving immunosuppressive drugs and corticosteroids at a mean dose of 46 mg prednisone equivalent daily (range, 30--80). Immunological reconstitution was incomplete in most of the patients as assessed by mean CD3, CD4 and CD8 lymphocyte count measured within few weeks before diagnosis: 0.7 G/L (range, 0.037--1.4), 0.26 G/L (0.011--0.74) and 0.43 G/L (0.02--1.07), respectively (UPN 9 had large granular lymphoproliferation (LGL) and was not included). All patients, except UPN 4, had been immunized against seasonal influenza and three patients had been vaccinated against H1N1 within a median of 19 days (range, 10--24) before symptom onset (UPN 2 and 3 were vaccinated 1 and 7 days, respectively, after the onset of symptoms) ([Table 1](#Tab1){ref-type="table"}).Table 1Baseline and clinical features of H1N1-infected patients at presentation*PatientsSex/age malignancyDonor type Cond RegKarnofsky score/chronic conditionsGvHD IS/CsBaseline CD3/CD4/CD8 (μL)Sampling site/H1N1 immunization-to-symptoms onset interval (D)Time since transplant (M)/symptom duration before diagnosis (D)Rhinorrhea/sore throat/dyspnea/myalgiaURTI/LRTIAssociated respiratory copathogensLOS (D)/mechanical ventilation duration (D)Oseltamivir/zanamivir duration (D)H275Y mutation/viral shedding (D)Outcome*UPN 1F/23HLSibRIC/UM100/NoneNone1423/310/1076NPS/−8/4Y/N/N/YY/NNone5/−5/−NAFullRecoveryUPN 2M/26ALLMUDMAC/T-dep100/NoneNone399/164/246NPS/+16/1Y/N/N/YY/NRSV Adenovirus---5/−N/NAFullRecoveryUPN 3F/32CMLSibMAC/T-dep100/NoneNone1039/744/264NPS/+7109/2Y/Y/N/YY/NNone---5/−N/NAFullRecoveryUPN 4M/49MMMUDMAC/UM70 /NoneExtensive Y/3037/11/22NPS+BAL/−12/4Y/N/Y/YY/YKlebsiella Oxytoca50/4315/15Y/12Expired D+54UPN 5F/62AMLSibRIC/T-dep80/DiabetesExtensive Y/80718/352/381NPS/−24^a^8/15N/N/Y/NN/YNone20/613/8N/19FullRecoveryUPN 6M/57NHLSibRIC/UM100/Esophageal cancerNoneNANPS/−1986/3Y/Y/Y/YY/NPicornavirus---6/−N/23FullRecoveryUPN 7M/40AMLSibMAC/T-dep70/Diabetes, Renal, pulmonaryExtensive Y/30861/121/691NPS+BAL/−52/1Y/N/Y/NY/YCMV EBV90/7020/20Y/21Expired D+94UPN 8M/56ALL Phi+SibRIC/UM80/pulmonaryExtensive Y/301005/376/646NPS/−10^a^22/4Y/Y/Y/NY/YNone---5/−N/NAFullRecoveryUPN 9M/52CMMLSibMAC/T-dep100/LGL, splenectomizedNone6630/580/5967NPS/−18/2Y/Y/Y/NY/NRSV---7/−NAFullRecoveryUPN 10M/53AMLSibRIC/T-dep70/Diabetes, renal, pulmonaryAcute Y/60141/16/115NPS/−8/2N/N/N/YN/YPicornavirus15/−15/15NAFullRecoveryAbbreviations: ALL Phi+=ALL Ph positive; BAL=bronchoalveolar lavage; CMML=chronic myelo-monocytic leukemia; Cond Reg=conditioning regimen; D=days; F=female; HL=Hodgkin\'s lymphoma; IS/C=immunosuppressive drug/corticosteroid (prednisone equivalent mg/day); LOS=length of stay; LRTI=lower respiratory tract infection; M=male; M=months; MAC=myeloablative conditioning; MM=multiple myeloma; MUD=matched unrelated donor; N=no; NA=not available; NHL=non-Hodgkin\'s lymphoma; NPS=nasopharyngeal swab; RIC=reduced-intensity conditioning; RSV=respiratory syncytial virus; Sib=identical sibling; T-dep=T-cell depletion; URTI=upper respiratory tract infection; UM=unmanipulated graft; Y=Yes.^a^UPN 5 and 8 had 2 vaccine doses (only time since first dose is specified).

Clinical features {#Sec8}
-----------------

All patients presented with fever and cough. Eight patients presented an URTI and five an LRTI (three patients had concomitant URTI and LRTI). The median duration of symptoms before virological diagnosis was 2.5 (range, 1--15) days. Commonly reported clinical manifestations were runny nose (*n*=8, 80%), myalgia (*n*=6, 60%) and dyspnea (*n*=6, 60%). Less common signs included sore throat (40%), gastrointestinal symptoms (20%), rarely sweating and fatigue. Abnormal physical examination findings were wheezes or rales on pulmonary auscultation (UPN 4, 5, 7, 8 and 10) and pharyngeal erythema (40% of patients). Chest X-rays were performed in seven patients. Alveolar or interstitial infiltrates were detected in two patients at presentation. Complete blood counts and serum chemistries were drawn in all patients at diagnosis, and revealed normal neutrophil counts in all cases and lymphopenia (\<1 /L) in six patients. Associated respiratory pathogens were present at diagnosis or developed during the disease course in six patients as shown in [Table 1](#Tab1){ref-type="table"}.

Serial virological testing was performed in three patients who required mechanical ventilation and in one patient who had persistent respiratory signs for 23 days, despite having received oseltamivir treatment (UPN 4, 5, 6 and 7). The median period of symptomatic viral shedding in those four patients was 22 (range, 19--81) days. Sequencing of the NA gene was performed on seven patients (not possible on the three remaining isolates mainly because of low viral loads). An oseltamivir-resistant strain appeared 7 and 6 days after initiation of oseltamivir in two patients (UPN 4 and 7), respectively, who later expired despite mechanical ventilation and i.v. zanamivir ([Table 1](#Tab1){ref-type="table"}).

Treatment and outcome {#Sec9}
---------------------

All patients were treated with oseltamivir at a dose of 75 mg two times a day. Treatment was started within a median of 3 (range, 0--8) days from symptom onset for a median duration of 6.5 (range, 5--20) days. Eight patients (80%) received broad spectrum antibiotics in addition to antiviral treatment.

Five patients of whom four (UPN 4, 5, 7 and 10) had significant comorbidities and active GvHD were hospitalized for a median of 20 (range, 5--90) days. Of the latter, three patients (UPN 4, 5 and 7) required mechanical ventilation for a median time of 43 (range, 6--70) days. Zanamivir was administered i.v. for these four patients (UPN 4, 5, 7 and 10) in addition to oseltamivir for a median duration of 15 (range, 8--20) days. Patients UPN 4 and 7 died of respiratory failure within 54 and 94 days of symptom onset, respectively, resulting in a case fatality rate of 20%. All patients tolerated oseltamivir and zanamivir, and none discontinued treatment because of adverse effects ([Table 1](#Tab1){ref-type="table"}).

Discussion {#Sec10}
==========

Several studies have described H1N1 infection in allo-HSCT ([Table 2](#Tab2){ref-type="table"}),^[@CR14],\ [@CR15],\ [@CR16],\ [@CR17],\ [@CR18],\ [@CR19]^ but its clinical spectrum is still being defined. Here, we report the impact of the H1N1 epidemic in a population of allo-HSCT recipients who were followed up in the long term in a clinic using standardized guidelines.^[@CR20]^Table 2Baseline and clinical features of H1N1-infected patients in the literature*Author countryNo. of patients* (% *of allo)Donor type/Cond RegMedian time since transplant (range)Median age (y) (range)GvHD* (%) *IS or CsVaccineRhinorrhea/Sore throat/dyspnea/myalgiaFever/cough/GI symptoms/CNS symptomsURTI LRTI* (%)*Antiviral treatmentHospital/mechanical ventilationH275Y mutation/PVSOutcome/mortality rate* (%)*Comments*This study10 (100%)2 MUD, 8 Sib/5 MAC, 5 RIC15 M (6--109)50.5 (23--62)5 (50%) 5H1N1: 5Seasonal: 98/4/6/610/10/2/085 (50%)O: 10Z: 45333Two deaths (20%)Taplitz *et al.*,^[@CR18]^ USA27 (80%)^a^12 MUD, 10 Sib/NA379 D (5--2895)46 (20--67)17 (63%) 12H1N1: 3Seasonal: NA12/10/16/1425/26/7/21314 (52%)O: 25Z: 5, P: 2NA71^b^NANine deaths (33%)19% NosocomialRedelman-Sidi *et al.*,^[@CR17]^ USA21 (57%)NA/19 MAC, 2 RIC44 M (5 M to 15 Y)36 (5--72)4 (19%) NANANANA9^c^6 (40%)O: 19Z: 18000Full recoveryNone nosocomial and none \<5 MTramontana *et al.*,^[@CR19]^ Australia16 (50%)^d^7 Sib, 1 MUD/NA3 allo \<100 D8 auto \>2 Y56.5 (30--72)5 (31%) 12H1N1: 0Seasonal: NANANA1611 (70%)O:15Z: 216931Six deaths (37,5 %)Three nosocomial and four with copathogens (aspergilus, CMV, Staph, HSV, HHV6, EBV)George *et al.*,^[@CR16]^ Australia13 (92%)3 MUD, 8 Sib, 1 Haplo/2 MAC, 10 RIC, 1 auto425 D (2--1541)53.6 (37--63)7 (54%) 5H1N1: NASeasonal: 9NA/13/5/NA13/11/NA/NA135 (40%)O: 13Z: 154NAFour deaths (30%)Five with copathogens and four had H1N1 before HSCTDitschkowski *et al.*,^[@CR28]^ Germany10 (NA)NA10 MNA5 (50%) 10NANANANAO: 1073NATwo deaths (20%)Garland *et al.*,^[@CR29]^ UK9 (44%)3 MUD, 1 Sib/1 MAC, 3 RIC, 5auto4 M (8 D to 6 Y)62 (35--75)NA3H1N1: 1Seasonal: NANANANAO: 9Z: 393NAThree deaths (20%)No copathogenPatel *et al.*,^[@CR27]^ USA5 (80%)1 MUD, 3 Sib/3 MAC, 1 RIC, 1 auto12 M (3--19)51 (23--56)4 (80%) 3H1N1: 0Seasonal: NANANA53 (60%)O: 5P: 111NA1One death (20%)One with parainfluenza, aspergillosis and rhizopusLalayanni *et al.*,^[@CR40]^ Greece3 (100%)NA18 M (15 M to 5 Y)40 (35--54)1NAH1N1: 1Seasonal: NANANA32 (66%)O: 3Z: 132NA1Two deaths (66%)CDC,^[@CR30]^ USA2 (NA)NA24 D10 and 40NANA1/NA/NA/NA2/2/NA/NA2NAO: 2, Z:1Rib: 1, R:12122Full recoveryOne with pneumocystis and staphKharfan-Dabaja *et al.*,^[@CR31]^ USA2 (100%)2 MUD/2RIC191 D (171--211)46.5 (41--52)22NANA/1/1/22/2/1/NA21O: 221NA0One deathOne with AspergillusBastos *et al.*,^[@CR41]^ Brazil1 (100%)CB/RIC3 D1201NA1/NA/1/NA1/1/NA/NA11O and Z11NA1Full recoveryNo copathogenRozovski *et al.*,^[@CR32]^ Israel1 (100%)1 Sib/RIC118 D6211NANA/NA/1/11/1/NA/11 1O11NADeathSepsis to Klebsiella pneumoniaFrangoul *et al.*,^[@CR42]^ USA1 (100%)CB/MAC7 Y911NANA/NA/1/NANo/NA/1 /NA00O11NADeathInfection mimicking gut GVHDCampbell *et al.*,^[@CR43]^ USA1 (0%)1 Auto2 D4000NANA/NA/No/NA1/1/1/NA11O, A, Rib, P11NA1DeathExtrapulmonary H1N1 RNAAbbreviations: ARDS=acute respiratory distress syndrome; ATG=anti-thymocyte globulin; Auto=autograft; CB=cord blood; Cond Reg=conditioning regimen; CNS=central nervous system; Cy=cyclophosphamid; D=days; Fluda=fludarabine; GI=gastrointestinal; Haplo=haplo-identical; HHV 6=human herpes virus 6; HSCT=hematopoietic SCT; IS/C=immunosuppressive drug/corticosteroid; LOS=length of stay; LRTI=lower respiratory tract infection; M=months; MAC=myeloablative conditioning; MMF=mycophenolate mofetil; MUD=matched unrelated donor; NA=not available; O=oseltamivir; P=peramivir; PVS=prolonged viral shedding; Rib=ribavirine; RIC=reduced-intensity conditioning; R=rimantadine; Ritux=rituximab; Sib=identical sibling; staph=staphylococcus; T-dep=T-cell depletion; URTI=upper respiratory tract infection; Y=year; y=years; Z=zanamivir.Data are number of patients unless otherwise specified. Only data on HSCT patients (allo and auto) provided in the articles are reported in the table.^a^Only 17 of 27 patients had a PCR-documented H1N1 infection (probable cases were defined as patients who had a positive test for influenza A in the context of widespread community H1N1 activity, without PCR confirmation).^b^Only one patient has been tested for H275Y mutation in this study.^c^Information on URTI or LRTI was lacking for six patients.^d^Some patients reported in this study might be common to those reported in the study by George *et al.*^[@CR16]^

H1N1 incidence peaked in November 2009, similar to the general Swiss population.^[@CR21]^ Overall, 4% of our total patient population had a proven H1N1 infection. When considering only those screened for a respiratory illness, ∼20% were infected. Redelman-Sidi *et al.*^[@CR17]^ found that 22% of their screened patients were positive for H1N1 during the New York city outbreak. In fact, the denominator of H1N1-infected patients is difficult to establish.^[@CR22],\ [@CR23]^ Whereas a frequency of 20% is most likely too high, 4% is certainly an underestimate if patients with mild illness may not have sought medical care and therefore may not have been diagnosed.

Nosocomial infection rates may range from 11 to 19% in allo-HSCTs.^[@CR15],\ [@CR18]^ Close contact with children was the most common presumed mode of transmission in our series, which is not surprising as this has been previously reported as the most significant risk factor of developing RVIs.^[@CR1]^ Indeed, approximately one child in every three was infected with H1N1 in England,^[@CR24]^ whereas in the United States, the rate of secondary outbreaks in households was 13% with children at increased risk for infection by a factor of 4.^[@CR25]^ Similarly, Kumar *et al.*^[@CR26]^ reported that pediatric solid organ transplant recipients were substantially more likely to have fever, rhinorrhoea, sore throat and headache at presentation than were adult patients. Notably in this study, 31% of patients had ill household contacts.^[@CR26]^ Taken together, these observations should alert physicians involved in the care of HSCT patients about the high risk of viral transmission through close contact with children, underlining the importance of education and vaccination of patients and their family households. Close contact with symptomatic children should be avoided whenever possible during periods of RVI epidemics.

Fever and cough were the most common symptoms observed. H1N1-related LRTI developed in 50%, of patients, which is in the range of 31--68% of almost all other series.^[@CR14],\ [@CR15],\ [@CR16],\ [@CR18],\ [@CR19],\ [@CR26],\ [@CR27]^ The 30% mechanical ventilation and 20% case fatality rates observed in our study correspond to those found in other small series,^[@CR16],\ [@CR18],\ [@CR19],\ [@CR27],\ [@CR28],\ [@CR29]^ but are higher than the frequencies reported in larger series (4.0--13.5% and 3.0--7.3%, respectively).^[@CR14],\ [@CR22],\ [@CR26]^ Although this may reflect a reporting bias if patients with more severe illness were more likely to come to medical attention, we believe that allo-HSCT recipients are at higher risk for severe complications, notably in case of development of H1N1 oseltamivir-resistant strains^[@CR15],\ [@CR19]^ or concomitant respiratory pathogens.^[@CR16],\ [@CR19],\ [@CR26],\ [@CR27],\ [@CR30],\ [@CR31],\ [@CR32]^

The average duration of H1N1 viral shedding in the general population was ∼6 days.^[@CR9],\ [@CR10],\ [@CR11]^ Redelman-Sidi *et al.*^[@CR17]^ failed to demonstrate a significant prolonged viral shedding in HSCT patients. However, we along with others^[@CR18],\ [@CR19],\ [@CR30]^ have found evidence of prolonged viral shedding in severely immunosuppressed allo-HSCTs and in patients with oseltamivir resistance. Although it remains uncertain whether these are representative of the entire population of allo-HSCTs, protracted infections are expected to occur in this patient population.

Half of our patients were classified as SID. Interestingly, LRTI, prolonged viral shedding, hospitalization, longer antiviral treatment, ventilator requirement and H1N1 resistance were documented only in SID patients. Lymphopenia, which has been previously reported as a risk factor for LRTI, both for community-acquired RVI^[@CR1],\ [@CR2],\ [@CR3],\ [@CR4],\ [@CR33]^ and for H1N1 influenza^[@CR9],\ [@CR14],\ [@CR15],\ [@CR16],\ [@CR17],\ [@CR18],\ [@CR26]^ was observed in six patients at the time of diagnosis. Chronic GvHD and its corollary of long-term immunosuppression has also been associated with the risk of developing RVI and LRTI.^[@CR1]^ Recently, Taplitz *et al.*^[@CR18]^ showed that the use of \>20 mg of prednisone equivalent daily was significantly associated with the development of LRTI and with 30-day mortality. In our study, 11% (5/46) of patients with active GvHD contracted an H1N1 infection as compared with 2.5% (5/202) of patients without GvHD (*P*\<0.03). Furthermore, 5 of 33 (15%) patients within the first year post transplant had an H1N1 infection, whereas only 5 of 215 (2.3%) patients after the first year were infected (*P*\<0.005). Taken together, these observations suggest that highly immunocompromised allo-HSCT recipients are at risk for severe complications from influenza and deserve close monitoring.

There have been conflicting data as to the efficacy of influenza immunization.^[@CR34],\ [@CR35],\ [@CR36]^ In our study, three patients had H1N1 infection despite having been vaccinated. In healthy adults, a single dose of H1N1 vaccine was highly immunogenic.^[@CR37]^ Ljungman^[@CR22]^ failed to demonstrate any protective effect from either the seasonal or the H1N1 vaccines in HSCT patients. In contrast, in the Spanish series,^[@CR14]^ only one of the vaccinated patients against seasonal influenza was diagnosed with pneumonia compared with 41% who were not vaccinated (*P*=0.005). Although it is not possible to draw definitive conclusions as to the protective effect of H1N1 vaccine in HSCT patients, preliminary results from a large study (<http://ClinicalTrials.gov>, ID: NCT01022905) conducted in our hospital suggest that severely immunocompromised allo-HSCT patients do not respond to H1N1 vaccination. Therefore, influenza vaccination of family members and close contacts, especially children, is strongly recommended to limit the risk of influenza exposure in HSCT recipients. Additional strategies such as post-exposure oseltamivir prophylaxis for high-risk patients may be warranted.^[@CR19],\ [@CR26],\ [@CR38]^

Our study has several limitations. The number of H1N1-confirmed cases was low, making the reliable estimation of clinical outcomes, such as mechanical ventilation or mortality rates, difficult. Furthermore, only a limited number of allo-HSCT recipients within 6 months post transplant (19 patients) were included, precluding us to precisely analyze the impact of H1N1 infection in the early post-transplant period.

In conclusion, although most allo-HSCT recipients had mild symptoms from H1N1 infection as does the general population,^[@CR23]^ high immunosuppression and emergence of oseltamivir-resistant strains were responsible for a substantial number of deaths in the allo-HSCT setting. Complications included higher rates of LRTI, prolonged viral shedding and respiratory failure. Our study strongly supports the need for vaccination and monitoring of family households, especially children.^[@CR39]^
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